NCT02447848View on ClinicalTrials.gov

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Moderate-to-severe Acute Pain
Interventions
DRUG

sufentanil sublingual 30 mcg tablet

Trial Locations (3)

55415

Hennepin County Medical Center, Minneapolis

77024

Hermann Memorial Medical Center, Houston

77030

Ben Taub General Hospital, Houston

All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

Talphera, Inc

INDUSTRY

NCT02447848 - Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain | Biotech Hunter | Biotech Hunter